Marine genetic resources: A review of scientific and commercial interest

Marine Policy

Volumn 33, Issue 2, 2009, Pages 183-194

  Leary, David ^a   Vierros, Marjo ^a   Hamon, Gwenaëlle ^b   Arico, Salvatore ^c   Monagle, Catherine ^a  

^a UNITED NATIONS UNIVERSITY   (Japan)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c Scientific and Cultural Organization   (France)

Author keywords

Bioprospecting in areas beyond national jurisdiction; Marine genetic resources; Marine scientific research and commercial applications

Indexed keywords

BIODIVERSITY; BIOINDICATOR; CONSERVATION PLANNING; GENETIC RESOURCE; MARINE POLICY; MARINE RESOURCE; NATURE CONSERVATION; RESOURCE USE;

EID: 57049092282     PISSN: 0308597X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.marpol.2008.05.010     Document Type: Article

References (92)

1. Report of the Ad Hoc Open-ended Informal Working Group to study issues relating to the conservation and sustainable use of marine biological diversity beyond areas of national jurisdiction, UN Doc A/61/65.
2. Leary D.K. International law and the genetic resources of the deep sea (2007), Martinus Nijhoff, Leiden, Boston
3. Ernst & Young, Beyond Borders: global biotechnology report 2007; 2007. Available on line at 〈http://www.ey.com/Global/assets.nsf/International/Industry_Biotech nology_Beyond_Borders_2007_Full/$file/BeyondBorders2007.pdf〉 .
4. International Assessment on Agricultural Science and Technology for Development (IAASTD). Available at 〈http://www.agassessment.org〉.
5. Verium Corporation, Case Study: FUELZYME-LF™ Enzyme, available at 〈http://www.verenium.com/Pages/Technology/EnzymeTech/TechEnzyFuelzy meLFCS.html〉.
6. Aguilar-Stoen M, Dhillion SS, Rosendal GK. Bioprospecting under different technological, biological and regulatory settings: trends and challenges. Environmental Science and Policy 2006. doi:10.1016/j.evsci.2006.07.003.
7. Available on line at 〈http://www.espacenet.com〉.
8. See 〈http://www.prialt.com/〉.
9. Haefner B. Drugs from the deep: marine natural products as drug candidates. Drug Discovery Today 8 12 (2003) 536-544
10. Busserolles J., Paya M., D'Auria M.V., Gomez-Paloma L., and Alcaraz M.J. Protection against 2,4,6-trinitrobenzenesulphonic acid-induced colonic inflammation in mice by the marine products bolinaquinone and petrosaspongiolide M. Biochemical Pharmacology 69 (2005) 1433-1440
11. Alcaraz M.J., and Paya M. Marine sponge metabolites for the control of inflammatory diseases. Current Opinion in Investigational Drugs 7 (2006) 974-979
12. Kitagawa I., and Kobayashi M. Antitumour marine natural products. Gan to KagakuRyoho Cancer and Chemotherapy 16 (1989) 1-8
13. Mayer A.M., and Lehmann V.K. Marine pharmacology in 1999: antitumor and cytotoxicic compounds. Anticancer Research 21 (2001) 2489-2500
14. Mayer A.M., and Gustafson K.R. Marine pharmacology in 2000: antitumour and cytotoxic compounds. International Journal of Cancer 105 (2003) 291-299
15. Mayer A.M., and Gustafson K.R. Marine pharmacology in 2001-2: antitumour and cytotoxic compounds. European Journal of Cancer 40 (2004) 2676-2704
16. Mayer A.M., and Gustafson K.R. Marine pharmacology in 2003-2004: antitumour and cytotoxic compounds. European Journal of Cancer 42 (2006) 2241-2270
17. Kitagawa I., and Kobayashi M. Antitumour marine natural products. Gan to KagakuRyoho Cancer and Chemotherapy 17 (1990) 322-329
18. Nagle D.G., Zhou Y.D., Mora F.D., Mohammed K.A., and Kim Y.P. Mechanism targeted discovery of antitumour marine natural products. Current Medical Chemistry 11 (2004) 1725-1756
19. Proksch P., Ebel R., Edrada R.A., Wray V., and Steube K. Bioactive natural products from marine invertebrates and associated fungi. Progress in Molecular and Subcellular Biology 37 (2003) 117-142
20. Calvert A.H. Fishing for new drugs. Journal of Clinical Oncology 23 (2005) 7780-7782
21. Zhang X.Y., Zhao Q.Y., Xue S., and Zhang W. Bioactive compounds from marine sponges and cell culture of marine sponges. Chinese Journal of Biotechnology 18 (2002) 10-15
22. Schwartzmann G., Da Rocha A.B., Mattei J., and Lopes R. Marine-derived anticancer agents in clinical trials. Expert Opinion on Investigational Drugs 12 (2003) 1367-1383
23. Roch P., Beschin A., and Bernard E. Anti-protozoa and antiviral activities of non-cytotoxic truncated and variant analogues of mussel defensin. eCAM 1 (2004) 207-209
24. Nuijen B., Bouma M., Manada C., Jimeno J.M., Schellens J.H., Bult A., et al. Pharmaceutical development of anticancer agents derived from marine sources. Anticanacer Drugs 11 (2000) 793-811
25. Taquchi T. Development of marine-derived anti-cancer compounds. Gan To Kagaku Ryoho Cancer and Chemotherapy 30 (2003) 579-588
26. Simmons T.L., Adrianasolo E., McPhail K., Flatt P., and Gerwicj W.H. Marine natural products as anticancer drugs. Molecular Cancer Therapeutics 4 (2005) 333-342
27. Whibley C.E., Keyzers R.A., Soper A.G., Davies-Coleman M.T., Samaai T., and Hendricks D.T. Antooesophageal cancer activity from Southern African marine organisms. Annals of the New York Academy of Sciences 1056 (2005) 405-412
28. Manzanares I., Cuevas C., Garcia-Nieto R., Marco E., and Gaqo F. Advances in the chemistry and pharmacology of ecteinascidins, a promising new class of anti-cancer agents. Current Medical Chemistry-Anti-Cancer Agents 1 (2001) 257-276
29. Jimeno J.M. A clinical armamentarium of marine-derived anti-cancer compounds. Anticancer Drugs 13 (2002) 15-19
30. Jimeno J., Lopez-Martin J.A., Ruiz-Casado A., Izquierdo M.A., Scheuer P.J., and Rinehart K. Progress in the clinical development of new marine-derived anticancer compounds. Anticancer Drugs 15 (2004) 321-329
31. Tan L.T. Bioactive natural products from marine cyanobacteria for drug discovery. Phytochemistry 68 (2007) 954-979
32. Den Brok M.W.J., Nuijen B., Miranda E., Floriano P., Munt S., Manzanares I., et al. Development and vamidation of a liquid chromatography-ultraviolet absorbance detection assay using derivatisation for the novel marine anti-cancer agent ES-285. HCl and its pharmaceutical dosage form. Journal of Chromatography A1020 (2003) 251-258
33. Zöllinger M., Kelter G., Fiebig H.H., and Lindel T. Antitumor activity of the marine natural product dibromophakellstatin in vitro. Bioorganic and Medical Chemistry Letters 17 (2007) 346-349
34. Ojika M., Kigoshi I., Yoshida Y., Ishigaki T., Nisiwaki M., Tsukada I., et al. Aplyronine A, a potent anti-tumor macrolide of marine origin, and the congeners aplyronines B and C: isolation, structures and bioactivities. Tetrahedron 63 (2007) 3138-3167
35. Tziveleka L.A., Vagias C., and Roussis V. Natural products with anti-HIV activity from marine organisms. Current Topics in Medicinal Chemistry 3 (2003) 1512-1535
36. Gochfeld D.J., El Sayed K.A., Yousaf M., Hu J.F., Bartyzel P., Dunbar D.C., et al. Marine natural products as lead anti-HIV agents. Mini Reviews in Med Chemistry 3 (2003) 401-424
37. Gul W., Hammond N.L., Yousaf M., Bowling J.J., Schinazi R.F., Wirtz S.S., et al. Modification at the C9 position of the marine natural product isoaaptamine and the impact on HIV-1, mycobacterial, and tumor cell activity. Bioorganic and Medical Chemistry 14 (2006) 8495-8505
38. Donia M., and Hamman M.T. Marine natural products and their potential applications as anti-infective agents. The Lancet Infectious Diseases 3 (2003) 338-348
39. Selvin J., Joseph S., Asha K.R.T., Manjusha W.A., Sangeetha V.S., Jayaseema D.M., et al. Antibacterial potential of antagonistic Streptomyces sp. isolated from marine sponge Dendrilla nigra. FEMS Microbiology Ecology 50 (2004) 117-122
40. Hamann M.T., Otto C.S., Scheuer P.J., and Dunbar D.C. Kahalalides: bioactive peptides from a marine mollusk Elysia rufescens and its algal diet Bryopsis sp. The Journal of Organic Chemistry 61 (1996) 6594-6600
41. Athukorala L., and Kim J. Anticoagulant activity of marine green and brown algae collected from Jeju Island in Korea. Bioresource Technology 98 (2007) 1711-1716
42. Green A. From alpha to omega-producing essential fatty acids in plants. Nature Biotechnology 22 (2004) 680-682
43. Spinney L. Fishing from Novel Drugs. Drug Discovery Today 8 17 (2003) 770-771
44. Arico S. Advances in concepts and methods for the marine environment: implications for policy. Cell Biology and Toxicology 2008; in press, doi:10.1007/S10565-008-90-68-8.
45. Cossins A.R., and Crawford D.L. Fish as models for environmental genomics. Nature Reviews Genetics 6 (2005) 324-340
46. Kim S.K., and Mendis E. Bioactive compounds from marine processing byproducts-a review. Food Research International 39 (2006) 383-393
47. Leary D. UNU-IAS Report. Bioprospecting in the Arctic. Yokohama, United Nations University, Institute of Advanced Studies, 2008.
48. Lohan D, Johnston S. UNU-IAS Report. Bioprospecting in Antarctica. Yokohama. United Nations University-Institute of Advanced Studies, 2005.
49. Weiner R.M. Biopolymers from marine prokaryotes. Trends in Marine Biotechnology 15 (1997) 390-394
50. Peng J., Sheng X., El Sayed K.A., Dunbar D.C., Perry T.L., Wilkins S.P., et al. Marine natural products as prototype agrochemical agents. Journal of Agriculture and Food Chemistry 9 (2003) 2246-2250
51. de Nys R., and Steinberg P.D. Linking marine biology and biotechnology. Current Opinion in Biotechnology 13 (2002) 244-248
52. Prieur D. Microbiology of deep-sea hydrothermal vents. TIBTECH 15 (1997) 242-244
53. Arico S., and Salpin C. Bioprospecting of genetic resources in the deep seabed: scientific, technical and legal aspects (2005), United Nations University Institute of Advanced Studies, Yokohama
54. Querellou J. Biotechnology from Marine Extremphiles' extended abstract. Available from 〈http://www.iasonnet.gr/abstracts/querelou.html〉.
55. Zanchetta P., Largarde N., and Guezennec J. A new bone-healing material: a hyaluronic acid-like bacteria Exopolysacchardide. Calcified Tissue International 72 1 (2003) 74-79
56. Juniper SK. Description of ecosystems of the deep seabed and impacts. In: Presentation to the fifth meeting of the United Nations Open-ended informal consultative process on oceans and the law of the sea, 7-11 June 2004. Available from 〈http://www.un.org/Depts/los/consultative_process.htm〉.
57. Deming J.W. Deep ocean biotechnology. Current Opinion in Biotechnology 9 3 (1998) 283-287
58. Colliec-Jouault S., Zanchetta P., Helley D., Ratiskol J., Sinquin C., Fischer A.M., et al. Les polysaccharides midcrobiens d'origine marine et leur potential en therapeutique humaine. Pathologie Biologie 52 3 (2004) 127-130
59. Blöchl E., Burggraf S., Fiala G., Lauerer G., Huber G., Huber R., et al. Isolation, taxonomy and phylogeny of hyperthermophilic microorganisms. World Journal of Microbiology and Biotechnology 11 1 (1995) 9-16
60. Vierros M., Douvere F., and Arico S. Implementing the ecosystem approach in open ocean and deep sea environments: an analysis of stakeholders, their interests and existing approaches (2006), United Nations University Institute of Advanced Studies, Yokohama
61. Arico S. Results of a national survey on marine biotechnology at the scientist and private sector levels: a case study of the US (abstract). In: International marine biotechnology conference, Sorrento, Paestum, Otranto and Pugnochiuso, Stazione Zoologica 'Anton Dohrn', 1997.
62. Faulkner D.J., and van Leeuwenhoek A. Marine pharmacology. Biomedical and Life Sciences 77 (2000) 135-145
63. Thoms C., and Schupp P. Biotechnological potential of marine sponges and their associated bacteria as producers of new pharmaceuticals (Part II). Journal of International Biotechnology Law 2 (2005) 257-264
64. Newman D.J., and Cragg G.M. Marine natural products and related compounds in clinical and advanced preclinical trials. Journal of Natural Products 67 (2004) 1216-1238
65. Harvey A. Strategies for discovering drugs from previously unexplored natural products. Drug Discovery 5 (2000) 294-300
66. Juniper SK. Deep-sea hydrothermal vent ecosystems-arguments for conservation. In: Third global conference on oceans, coasts and small Islands, Conference's background material. Available at 〈http://www.globaloceans.org/globalconferences/2006/materials. html〉.
67. Christoffersen LP, Mathur EJ. Bioprospecting ethics and benefits: a model for effective benefit-sharing. Industrial Biotechnology 2005;1(4):255-9. Available at: 〈http://www.liebertpub.com/publication.aspx?pub_id=140〉.
68. Committee on Marine Biotechnology: Biomedical Applications of Marine Natural Products. Marine biotechnology in the twenty-first century: problems, promise, and products (2002), National Academy Press, Washington, DC
69. Ernst and Young. Beyond borders: the global biotechnology report 2006. 2006, available at 〈http://webapp01.ey.com.pl/EYP/WEB/eycom_download.nsf/resources/BB2 006_Global.pdf/$FILE/BB2006GlobalPerspective.pdf〉.
70. Ruth L. Gambling in the deep sea. EMBO report 2006 January, vol. 7(1), p. 17-21. doi:10.1038/sj.embor.7400609. Science and Society Analysis. 〈http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid= 1369241〉.
71. IMS Health, available at 〈http://www.imshealth.com〉.
72. See 〈http://www.marinebiotech.org/devpartners.html〉.
73. Cole A. Looking for new compounds in sea is endangering ecosystem. British Medical Journal 2005;330:1350 (11 June), doi:10.1136/bmj.330.7504.1350-d 〈http://www.bmj.com/cgi/content/full/330/7504/1350-d〉.
74. See 〈http://www.marinebiotech.org/devpartners.html〉.
75. Yondelis. Available at 〈http://www.pharmamar.com/en/pipeline/yondelis.cfm〉.
76. Kahalalide F. Available at 〈http://www.pharmamar.com/en/pipeline/kahalalide.cfm〉.
77. Avastin historical sales. Available from 〈http://www.gene.com/gene/ir/financials/historical/avastin. html〉.
78. Herceptin historical sales. Available from 〈http://www.gene.com/gene/ir/financials/historical/herceptin. html〉.
79. See 〈http://www.elan.com/InvestorRelations/financials/〉.
80. Marine bioprospecting: mining the untapped potential of living marine resources. Available from 〈http://www.marinebiotech.org/biopro.html〉.
81. GSK's Patent on Retrovir Expires; Generic Versions of AZT Expected To Be Available Soon. Available from 〈http://www.medicalnewstoday.com/articles/30949.php〉.
82. 〈http://money.cnn.com/2005/07/06/news/fortune500/aids/index. htm〉.
83. World Enzymes. Available from 〈http://www.marketresearch.com/map/prod/1559904.html〉.
84. Marshall C. Bioprospectors mine nature of genetic gold. Forbes.com 2000. Available at 〈http://www.forbes.com/2000/05/29/feat.html〉.
85. Carvajal D. Primping for the cameras in the name of research. New York Times, February 7, 2006. Available from 〈http://www.nytimes.com/2006/02/07/business/07hair.html?_r=2&or ef=slogin&pagewanted=all&oref=slogin〉.
86. Euromonitor International. Cosmetics and Toiletries. Available from 〈http://www.euromonitor.com/cosmetics〉.
87. Pitman S. Greying population ups anti-ageing stakes. Cosmetics-design Europe 2004. Available from 〈http://www.cosmeticsdesign-europe.com/news/ng.asp?id=56694-greying -population-ups〉.
88. Mulligan M. Searching for the fountain of youth. Forbes.com 2002. Available at 〈http://www.forbes.com/2002/06/17/0617sf.html〉.
89. See 〈http://www.clarisn.com〉.
90. See 〈http://www.cyanotech.com/〉.
91. See 〈http://www.krill-oil.biz/〉.
92. See 〈http://www.akerbiomarine.com/〉.